Is Investing in Syneos Health (SYNH) Risky?

Carillon Tower Advisers, an investment management company, released its “Carillon Chartwell Mid Cap Value Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. The market witnessed extreme volatility in the quarter, and the equity market segment returns ranged from -2% to -5%. The Russell Mid Cap Value index declined nearly 5% in the quarter. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Carillon Tower highlighted stocks like Syneos Health, Inc. (NASDAQ:SYNH) in the Q3 2022 investor letter. Headquartered in Morrisville, North Carolina, Syneos Health, Inc. (NASDAQ:SYNH) is a biopharmaceutical company. On November 18, 2022, Syneos Health, Inc. (NASDAQ:SYNH) stock closed at $32.63 per share. One-month return of Syneos Health, Inc. (NASDAQ:SYNH)  was -30.38%, and its shares lost 67.74% of their value over the last 52 weeks. Syneos Health, Inc. (NASDAQ:SYNH)  has a market capitalization of $3.358 billion.

Carillon Tower made the following comment about Syneos Health, Inc. (NASDAQ:SYNH)  in its Q3 2022 investor letter:

Syneos Health, Inc. (NASDAQ:SYNH) is a contract research organization serving the biotech industry. Weakness in the capital markets has been particularly acute for venture stage companies, threatening funding for the company’s customers. A decline in bookings in the most recent quarter highlighted this risk for investors.”

Pressmaster/Shutterstock.com

Syneos Health, Inc. (NASDAQ:SYNH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 33 hedge fund portfolios held Syneos Health, Inc. (NASDAQ:SYNH) at the end of the third quarter, which was 28 in the previous quarter.

We discussed Syneos Health, Inc. (NASDAQ:SYNH) in another article and shared ClearBridge Investments’ views on the company. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.